The post Dogecoin ETFs Record Zero Net Inflows appeared on BitcoinEthereumNews.com. The trio of spot Dogecoin exchange-traded funds, Grayscale’s GDOG, 21Shares,The post Dogecoin ETFs Record Zero Net Inflows appeared on BitcoinEthereumNews.com. The trio of spot Dogecoin exchange-traded funds, Grayscale’s GDOG, 21Shares,

Dogecoin ETFs Record Zero Net Inflows

For feedback or concerns regarding this content, please contact us at [email protected]

The trio of spot Dogecoin exchange-traded funds, Grayscale’s GDOG, 21Shares, and Bitwise  recorded $0 in daily net inflows on Monday, according to Sosovalue data. The figure reflects a pattern that has dominated trading since early February and echoes similar stretches seen throughout December and January.

Since Feb. 3, the Dogecoin ETFs have posted zero daily net inflows on most trading days. Minor activity has occurred, with total value traded ranging between $150,000 and $1.37 million during this period. A handful of days registered net inflows, but those were offset by outflows that returned the trend to flat.

Weak Demand Has Persisted Since Launch

The muted performance dates back to the products’ debut. Grayscale’s GDOG launched with approximately $1.4 million in trading volume, a figure well below analyst expectations and far beneath the demand levels seen for Bitcoin and Ethereum ETFs at launch.

A brief reprieve emerged at the start of 2026. Dogecoin and other meme coins led a sharp crypto bounce in early January, and the 2x Dogecoin ETF outperformed its peers during that stretch. The rally, however, was short-lived. Prices reversed quickly, and Dogecoin entered the new year on a deteriorating trend that carried into February.

The ETFs have simply tracked the underlying asset’s weakness. When a token declines consistently, fund flows tend to dry up in parallel. There is little institutional incentive to allocate capital to a declining asset with no fundamental catalyst for recovery.

Five Months of Losses Weigh on Sentiment

Dogecoin has fallen for five consecutive months since September 2025. The losses extended into January and February 2026, making the first two months of the year among the weakest for the token in recent memory.

The broader crypto environment has compounded the pressure. When Bitcoin trades within a tight range, speculative capital often rotates into meme coins, which do not require macro drivers to attract volume. However, when sentiment turns negative across the market, meme coins typically absorb the steepest losses. Dogecoin has followed this pattern closely.

At the time of writing, Dogecoin was trading at $0.09542, up 2.81% over the prior 24 hours. 

Source: https://coinpaper.com/15099/dogecoin-et-fs-zero-net-inflows-persist-as-doge-price-struggles

Market Opportunity
Ucan fix life in1day Logo
Ucan fix life in1day Price(1)
$0.0004868
$0.0004868$0.0004868
-6.65%
USD
Ucan fix life in1day (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09